Sufficient quantity for effective treatment |
|---|
for the therapy of thromboembolic diseases such as myocardial infarction, pulmonary embolism, stroke and deep venous thrombosis. It was developed by Boehringer Ingelheim Germany and Genentech, USA and launched in 1987. Clinical trials have shown that recombinant tPA is superior to other thrombolytic substances, working faster, causing fewer side effects and reducing mortality in patients with myocardial infarction. The recombinant product is produced in mammalian cells in serum free medium and there is no risk of viral contamination. Already, genetic engineering has been shown to be of great benefit to patients who require protein substitution therapies, and for the first time in history this substance can be produced in sufficient quantity.